FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:810-820 August 21, 2008 Number 8 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF antibody, in children with polyarticular-course juvenile rheumatoid arthritis.

Methods Patients 4 to 17 years of age with active juvenile rheumatoid arthritis who had previously received treatment with nonsteroidal antiinflammatory drugs underwent stratification according to methotrexate use and received 24 mg of adalimumab per square meter of body-surface area (maximum dose, 40 mg) subcutaneously every other week for 16 weeks. We randomly assigned patients with an American College of Rheumatology Pediatric 30% (ACR Pedi 30) response at week 16 to receive adalimumab or placebo in a double-blind fashion every other week for up to 32 weeks.

Results Seventy-four percent of patients not receiving methotrexate (64 of 86) and 94% of those receiving methotrexate (80 of 85) had an ACR Pedi 30 response at week 16 and were eligible for double-blind treatment. Among patients not receiving methotrexate, disease flares (the primary outcome) occurred in 43% of those receiving adalimumab and 71% of those receiving placebo (P=0.03). Among patients receiving methotrexate, flares occurred in 37% of those receiving adalimumab and 65% of those receiving placebo (P=0.02). At 48 weeks, the percentages of patients treated with methotrexate who had ACR Pedi 30, 50, 70, or 90 responses were significantly greater for those receiving adalimumab than for those receiving placebo; the differences between patients not treated with methotrexate who received adalimumab and those who received placebo were not significant. Response rates were sustained after 104 weeks of treatment. Serious adverse events possibly related to adalimumab occurred in 14 patients.

Conclusions Adalimumab therapy seems to be an efficacious option for the treatment of children with juvenile rheumatoid arthritis. (ClinicalTrials.gov number, NCT00048542 [ClinicalTrials.gov] .)

Source Information

The authors' affiliations are listed in the Appendix.

Drs. Lovell and Ruperto contributed equally to this article.

Address reprint requests to Dr. Lovell at Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Location E, Rm. 2-129, MLC 4010, 3333 Burnet Ave., Cincinnati, OH 45229-3039, or at daniel.lovell{at}cchmc.org.

Full Text of this Article

Related Letters:

Adalimumab in Juvenile Rheumatoid Arthritis
Sfriso P., Ravaioli F., Taddio A., Marchetti F., de Vries M. K., van der Horst-Bruinsma I. E., Wolbink G. J., Lovell D. J., Ruperto N.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:2495-2497, Dec 4, 2008. Correspondence

This article has been cited by other articles:

• Lionaki, S., Siamopoulos, K., Theodorou, I., Papadimitraki, E., Bertsias, G., Boumpas, D., Boletis, J. (2009). Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study. Nephrol Dial Transplant 24: 2144-2150 [Abstract] [Full Text]  
• Sfriso, P., Ravaioli, F., Taddio, A., Marchetti, F., de Vries, M. K., van der Horst-Bruinsma, I. E., Wolbink, G. J., Lovell, D. J., Ruperto, N. (2008). Adalimumab in Juvenile Rheumatoid Arthritis. NEJM 359: 2495-2497 [Full Text]  
• Li, S. C. (2008). Another Biologic Agent for the Treatment of Juvenile Arthritis. AAP Grand Rounds 20: 54-55 [Full Text]  
• (2008). TNF Antagonists for Treatment of Juvenile Rheumatoid Arthritis. JWatch General 2008: 6-6 [Full Text]